<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">urovest</journal-id><journal-title-group><journal-title xml:lang="ru">Вестник урологии</journal-title><trans-title-group xml:lang="en"><trans-title>Urology Herald</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2308-6424</issn><publisher><publisher-name>Rostov State Medical University</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21886/2308-6424-2018-6-1-55-64</article-id><article-id custom-type="elpub" pub-id-type="custom">urovest-192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ ЛИТЕРАТУРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS ARTICLE</subject></subj-group></article-categories><title-group><article-title>ОНКОУРОЛОГИЧЕСКАЯ МУЛЬТИДИСЦИПЛИНАРНАЯ ГРУППА ‒ СОВРЕМЕННАЯ ФОРМА АКТИВНОГО КОЛЛЕГИАЛЬНОГО ВЗАИМОДЕЙСТВИЯ МЕЖДУ КЛИНИЦИСТОМ И ПАТОЛОГОАНАТОМОМ</article-title><trans-title-group xml:lang="en"><trans-title>ONCOUROLOGICAL MULTIDISCIPLINARY TEAM IS A CONTEMPORARY FORM OF ACTIVE COLLEGIAL COOPERATION BETWEEN THE CLINICIANS AND PATHOLOGISTS</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8145-5733</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фридман</surname><given-names>Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Fridman</surname><given-names>E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>заведующий отделом уро-патологии института патологии;</p><p>доцент медицинского факультета,</p><p>Тель-Авив</p></bio><bio xml:lang="en"><p>MD, Head of Uro-Pathology Unit, Department of Pathology;</p><p>The Sackler Medical School, </p><p>Tel-Aviv</p></bio><email xlink:type="simple">Eddie.Fridman@sheba.health.gov.il</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Медицинский Центр имени Хаима Шибы; &#13;
Тель-Авивский университет Рамат-Ган</institution><country>Израиль</country></aff><aff xml:lang="en"><institution>Chaim Sheba Medical Center;&#13;
Tel-Aviv University Ramat-Gan</institution><country>Israel</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2018</year></pub-date><pub-date pub-type="epub"><day>31</day><month>03</month><year>2018</year></pub-date><volume>6</volume><issue>1</issue><fpage>55</fpage><lpage>64</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Фридман Э., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Фридман Э.</copyright-holder><copyright-holder xml:lang="en">Fridman E.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.urovest.ru/jour/article/view/192">https://www.urovest.ru/jour/article/view/192</self-uri><abstract><p>В 2014 году отмечалась 130-я годовщина публикации Grawitz, в которой утверждалось, что рак почки имеет надпочечноe происхождениe (отсюда название «гипернефрома»). Споры продолжались до середины двадцатого столетия, когда развитие электронного микроскопа дало окончательные доказательства того, что эти опухоли происходят из канальцевого эпителия почки, как утверждал Вирхов. Этот период противоречий вокруг ‘hypernephroma’ дал развитие патологической анатомии, а также стал точкой утверждения уропатологии, как правомочной субспециализации в патологии.</p><p>В течение этого периода были разработаны множественные классификации опухолей органов мужской мочеполовой системы, оценки степени гистологической дифференциации злокачественных опухолей, которые вошли в практику. Введение иммуногистохимии и недавнее появление цитогенетических методов имело огромное влияние на повышение роли патолога в уточнении и стандартизации морфологических критериев диагностики опухолей мочеполового тракта.</p><p>Параллельно произошло широкое введение тестирования крови на простатический специфический антиген (PSA) и разработка техники тонкоигольчатой биопсии предстательной железы. Последствия этих технологических прорывов трудно переоценить в воздействии на клиническую практику в мире. Такое усиление клинического интереса к раннему диагнозу и, следовательно, к способам лечения рака предстательной железы привело к расширению научных исследований, связанных с морфологией простатой. Из-за быстрого расширения знаний в этиологии и патогенезе, а также клиники и биологического поведе-ния многих форм опухолей мочеполовой системы организация мультидисциплинарных онкологических команд с участием уро-патологов очень своевременна. Такое сотрудничество в урологической онкологии между урологами, онкологами и патологами обеспечит более полное понимание состояния больного, процесса развития опухоли, проблем диагностики и полноправного участия патолога в диагностике и лечении больного. Создание таких групп позволит осуществить более комплексный подход в понимании современного состояния проблем рака, направлений дальнейшего развития в исследовании этих проблем и будет полезным как самому больному, а также клиническим врачам (урологам и онкологам), так и диагностическим патологам. Такое сотрудничество однозначно положительно и довольно быстро отразится на повышении профессионального самосознания патологов в качестве «диагностических онкологов». Создание подобной формы междисциплинарного сотрудничества может и должно стать примером создания подобных команд и в смежных специальностях. Основы построения таких команд и их влияние на лечение больных в каждодневной практике рассматриваются в данной статье.</p></abstract><trans-abstract xml:lang="en"><p>In 2014, we celebrated 130 anniversary of Grawitz’s report suggesting that the renal carcinoma originates from intrarenal adrenal rests and the name «hypernehproma» was subsequently accepted. The discussions continued until the middle of 20th century when electron microscopic studies finally approved the Virchow’s postulates and showed that the renal tumors originate from the canalicular epithelium. This period became to be also a keystone for uropathology as independent sub-specialization in pathology.</p><p>During that period numerous classification of male genital tract tumors were accepted, as well as the histological grading of the tumors, which started to be a part of routine medical practice. The invention of immunohistochemistry and new cytogenetic techniques affected a great influence and increased the significance of role of pathologist in detailed assessment and standardization of morphological criteria of urological tumors.</p><p>Side by side, the wide applying of blood test for prostatic specific antigen (PSA) and invention of fineneedle prostatic biopsy technique were performed. The results of this technological breakthrough influenced dramatically to worldwide clinical practice. Such increased clinical interest for early diagnosis and treatment of prostatic cancer made push to wide range of scientific investigations, concerning the morphology of prostate. Due to rapid growth of knowledge about etiology and pathogenesis, as well as biological behavior the different urological malignancies, the significance of multidisciplinary teams (MDT) with participation of urologists, oncologists and pathologists is essential. Such co-operation in urological oncology provides better understanding of the patient’s status, his tumor diagnosis, stage and treatment of the patient. Therefore, participation of the pathologist is the as equal among equals. Such teams can offer more detailed consideration and modern attitude to the oncological problems and can help to design new directions that will be useful to both, patients and clinical physicians (oncologists and urologists), as well as diagnostic pathologists. This co-operation will rapidly increase the self-awareness of the pathologist as ‘diagnostic oncologist’. These multidisciplinary teams might be a good example for other specializations in practical medicine and the organization of such teams and there guidance to the everyday practice is the main aim of this article.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>патоморфология</kwd><kwd>уропатологии</kwd><kwd>субспециализация</kwd><kwd>тонкоигольчатая биопсия</kwd><kwd>предстательная железа</kwd><kwd>стандарты</kwd><kwd>мультидисциплинарная онкологическая команда</kwd><kwd>сотрудничество</kwd></kwd-group><kwd-group xml:lang="en"><kwd>pathomorphology</kwd><kwd>uropathology</kwd><kwd>sub-specialization</kwd><kwd>fine needle biopsy</kwd><kwd>prostate</kwd><kwd>standards</kwd><kwd>multidisciplinary team</kwd><kwd>co-opreration</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Srigley JR.: The pathologist as diagnostic oncologist. Pathology. 2009;41(6):513-514.</mixed-citation><mixed-citation xml:lang="en">Srigley JR.: The pathologist as diagnostic oncologist. Pathology. 2009;41(6):513-514.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Delahunt B. Editorial: Genitourinary pathology 120 years. Pathology. 2003;35(6):465-6.</mixed-citation><mixed-citation xml:lang="en">Delahunt B. Editorial: Genitourinary pathology 120 years. Pathology. 2003;35(6):465-6.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Bailar JC 3rd, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation—preliminary report. Cancer Chemother Rep. 1966;50:129-136.</mixed-citation><mixed-citation xml:lang="en">Bailar JC 3rd, Mellinger GT, Gleason DF. Survival rates of patients with prostatic cancer, tumor stage, and differentiation—preliminary report. Cancer Chemother Rep. 1966;50:129-136.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mellinger GT, Gleason D, Bailar J III. The histology and prognosis of prostatic cancer. J Urol. 1967;97(2):331-337.</mixed-citation><mixed-citation xml:lang="en">Mellinger GT, Gleason D, Bailar J III. The histology and prognosis of prostatic cancer. J Urol. 1967;97(2):331-337.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Mellinger GT. Prognosis of prostatic carcinoma. Recent Results Cancer Res. 1977;60:61-72.</mixed-citation><mixed-citation xml:lang="en">Mellinger GT. Prognosis of prostatic carcinoma. Recent Results Cancer Res. 1977;60:61-72.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996;20(7):802-814.</mixed-citation><mixed-citation xml:lang="en">McNeal JE, Yemoto CE. Spread of adenocarcinoma within prostatic ducts and acini. Morphologic and clinical correlations. Am J Surg Pathol. 1996;20(7):802-814.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Powsner SM, Costa J, Homer RJ. Clinicians are from Mars and pathologists are from Venus. Arch Pathol Lab Med. 2000;124(7):1040-6. doi: 10.1043/0003-9985(2000)1242.0.CO;2</mixed-citation><mixed-citation xml:lang="en">Powsner SM, Costa J, Homer RJ. Clinicians are from Mars and pathologists are from Venus. Arch Pathol Lab Med. 2000;124(7):1040-6. doi: 10.1043/0003-9985(2000)1242.0.CO;2</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015;47(1):1-3. doi: 10.1097/PAT.0000000000000186</mixed-citation><mixed-citation xml:lang="en">Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology. 2015;47(1):1-3. doi: 10.1097/PAT.0000000000000186</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, de la Taille A. What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer? European Urology. 2005;48(6):911-5. doi: 10.1016/j.eururo.2005.07.011</mixed-citation><mixed-citation xml:lang="en">Descazeaud A, Rubin MA, Allory Y, Burchardt M, Salomon L, Chopin D, Abbou C, de la Taille A. What information are urologists extracting from prostate needle biopsy reports and what do they need for clinical management of prostate cancer? European Urology. 2005;48(6):911-5. doi: 10.1016/j.eururo.2005.07.011</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bostwick DG, Meiers I. Prostate Biopsy and Optimization of Cancer Yield. European Urology. 2006;49(3):415-417. doi: 10.1016/j.eururo.2005.12.052.</mixed-citation><mixed-citation xml:lang="en">Bostwick DG, Meiers I. Prostate Biopsy and Optimization of Cancer Yield. European Urology. 2006;49(3):415-417. doi: 10.1016/j.eururo.2005.12.052.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Ficarra V, Martignoni G, Novella G, Cerruto MA, Galfano A, Novara G, Pea M, Artibani W. Needle core length is a quality indicator of systematic transperineal prostate biopsy. Eur Urol. 2006;50(2):266-71. doi: 10.1016/j. eururo.2005.12.057</mixed-citation><mixed-citation xml:lang="en">Ficarra V, Martignoni G, Novella G, Cerruto MA, Galfano A, Novara G, Pea M, Artibani W. Needle core length is a quality indicator of systematic transperineal prostate biopsy. Eur Urol. 2006;50(2):266-71. doi: 10.1016/j. eururo.2005.12.057</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF; Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol. 2003;56(5):336-40.</mixed-citation><mixed-citation xml:lang="en">van der Kwast TH, Lopes C, Santonja C, Pihl CG, Neetens I, Martikainen P, Di Lollo S, Bubendorf L, Hoedemaeker RF; Members of the pathology committee of the European Randomised Study of Screening for Prostate Cancer. Guidelines for processing and reporting of prostatic needle biopsies. J Clin Pathol. 2003;56(5):336-40.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) r6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36:1346-1352.</mixed-citation><mixed-citation xml:lang="en">Ross HM, Kryvenko ON, Cowan JE, Simko JP, Wheeler TM, Epstein JI. Do adenocarcinomas of the prostate with Gleason score (GS) r6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012;36:1346-1352.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Berman DM, Epstein JI. When is prostate cancer really cancer? Urol Clin North Am. 2014;41(2):339-346. doi: 10.1016/j.ucl.2014.01.006</mixed-citation><mixed-citation xml:lang="en">Berman DM, Epstein JI. When is prostate cancer really cancer? Urol Clin North Am. 2014;41(2):339-346. doi: 10.1016/j.ucl.2014.01.006</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol. 2012;30(35):4294-6. doi: 10.1200/ JCO.2012.44.0586</mixed-citation><mixed-citation xml:lang="en">Carter HB, Partin AW, Walsh PC, Trock BJ, Veltri RW, Nelson WG, Coffey DS, Singer EA, Epstein JI. Gleason score 6 adenocarcinoma: should it be labeled as cancer? J Clin Oncol. 2012;30(35):4294-6. doi: 10.1200/ JCO.2012.44.0586</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):e234-42. doi: 10.1016/S1470-2045(13)70598-9</mixed-citation><mixed-citation xml:lang="en">Esserman LJ, Thompson IM, Reid B, Nelson P, Ransohoff DF, Welch HG, Hwang S, Berry DA, Kinzler KW, Black WC, Bissell M, Parnes H, Srivastava S. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol. 2014;15(6):e234-42. doi: 10.1016/S1470-2045(13)70598-9</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol. 2009;182(2):485-90. doi: 10.1016/j.juro.2009.04.016</mixed-citation><mixed-citation xml:lang="en">Merrimen JL, Jones G, Walker D, Leung CS, Kapusta LR, Srigley JR. Multifocal high grade prostatic intraepithelial neoplasia is a significant risk factor for prostatic adenocarcinoma. J Urol. 2009;182(2):485-90. doi: 10.1016/j.juro.2009.04.016</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125-128.</mixed-citation><mixed-citation xml:lang="en">Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50(3):125-128.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.</mixed-citation><mixed-citation xml:lang="en">Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol. 1974;111(1):58-64.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228-1242.</mixed-citation><mixed-citation xml:lang="en">Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL; ISUP Grading Committee. The 2005 international society of urological pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2005;29(9):1228-1242.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch. 2006;449(6):622-627. doi: 10.1007/s00428-006-0310-6</mixed-citation><mixed-citation xml:lang="en">Helpap B, Egevad L. The significance of modified Gleason grading of prostatic carcinoma in biopsy and radical prostatectomy specimens. Virchows Arch. 2006;449(6):622-627. doi: 10.1007/s00428-006-0310-6</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committe. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244-52. doi: 10.1097/ PAS.0000000000000530</mixed-citation><mixed-citation xml:lang="en">Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committe. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2016;40(2):244-52. doi: 10.1097/ PAS.0000000000000530</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Grignon DJ. Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens. Modern Pathology. 2018;31(S1):S96-109. doi: 10.1038/ modpathol.2017.167</mixed-citation><mixed-citation xml:lang="en">Grignon DJ. Prostate cancer reporting and staging: needle biopsy and radical prostatectomy specimens. Modern Pathology. 2018;31(S1):S96-109. doi: 10.1038/ modpathol.2017.167</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason Grading of Prostatic Carcinoma An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2017;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820</mixed-citation><mixed-citation xml:lang="en">Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason Grading of Prostatic Carcinoma An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol. 2017;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Fine SW, Epstein JI. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol. 2008;179(4):1335-8. doi: 10.1016/j.juro.2007.11.057</mixed-citation><mixed-citation xml:lang="en">Fine SW, Epstein JI. A contemporary study correlating prostate needle biopsy and radical prostatectomy Gleason score. J Urol. 2008;179(4):1335-8. doi: 10.1016/j.juro.2007.11.057</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, Reuter VE, Sakr WA, Srigley JR, Wheeler TM, Yang XJ, Epstein JI. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008;32(10):1532-9. doi: 10.1097/ PAS.0b013e318169e8fd</mixed-citation><mixed-citation xml:lang="en">Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, Reuter VE, Sakr WA, Srigley JR, Wheeler TM, Yang XJ, Epstein JI. Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology. Am J Surg Pathol. 2008;32(10):1532-9. doi: 10.1097/ PAS.0b013e318169e8fd</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21(5):566-576.</mixed-citation><mixed-citation xml:lang="en">Steinberg DM, Sauvageot J, Piantadosi S, Epstein JI. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol. 1997;21(5):566-576.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753-60. doi: 10.1111/j.1464-410X.2012.11611.x</mixed-citation><mixed-citation xml:lang="en">Pierorazio PM, Walsh PC, Partin AW, Epstein JI. Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. BJU Int. 2013;111(5):753-60. doi: 10.1111/j.1464-410X.2012.11611.x</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A contemporary prostate cancer grading system: a validated alternative to Gleason score. Eur Urol. 2016;69(3):428-35. doi: 10.1016/j. eururo.2015.06.046</mixed-citation><mixed-citation xml:lang="en">Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA. A contemporary prostate cancer grading system: a validated alternative to Gleason score. Eur Urol. 2016;69(3):428-35. doi: 10.1016/j. eururo.2015.06.046</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: General Pathologists. Hum Pathol. 2001;32(1):81-8. doi: 10.1053/ hupa.2001.21135</mixed-citation><mixed-citation xml:lang="en">Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Epstein JI. Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: General Pathologists. Hum Pathol. 2001;32(1):81-8. doi: 10.1053/ hupa.2001.21135</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI. Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: Urologic Pathologists General Pathologists. Hum Pathol. 2001;32(1):74-80. doi: 10.1053/hupa.2001.21134</mixed-citation><mixed-citation xml:lang="en">Allsbrook WC Jr, Mangold KA, Johnson MH, Lane RB, Lane CG, Amin MB, Bostwick DG, Humphrey PA, Jones EC, Reuter VE, Sakr W, Sesterhenn IA, Troncoso P, Wheeler TM, Epstein JI. Interobserver Reproducibility of Gleason Grading of Prostatic Carcinoma: Urologic Pathologists General Pathologists. Hum Pathol. 2001;32(1):74-80. doi: 10.1053/hupa.2001.21134</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Fleshner NE., Evans A., Chadwick K., Lawrentschuk N., Zlotta A. Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol. 2010;28(2):197-204. doi: 10.1016/j.urolonc.2009.08.015</mixed-citation><mixed-citation xml:lang="en">Fleshner NE., Evans A., Chadwick K., Lawrentschuk N., Zlotta A. Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol. 2010;28(2):197-204. doi: 10.1016/j.urolonc.2009.08.015</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L; ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Specimen handling. Mod Pathol. 2011;24(1):6-15. doi: 10.1038/ modpathol.2010.178</mixed-citation><mixed-citation xml:lang="en">Samaratunga H, Montironi R, True L, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Wheeler TM, Srigley JR, Delahunt B, Egevad L; ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Specimen handling. Mod Pathol. 2011;24(1):6-15. doi: 10.1038/ modpathol.2010.178</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011;24(1):16-25. doi: 10.1038/modpathol.2010.156</mixed-citation><mixed-citation xml:lang="en">van der Kwast TH, Amin MB, Billis A, Epstein JI, Griffiths D, Humphrey PA, Montironi R, Wheeler TM, Srigley JR, Egevad L, Delahunt B; ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol. 2011;24(1):16-25. doi: 10.1038/modpathol.2010.156</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA; ISUP Prostate Cancer Group. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011;24(1):26-38. doi: 10.1038/ modpathol.2010.158</mixed-citation><mixed-citation xml:lang="en">Magi-Galluzzi C, Evans AJ, Delahunt B, Epstein JI, Griffiths DF, van der Kwast TH, Montironi R, Wheeler TM, Srigley JR, Egevad LL, Humphrey PA; ISUP Prostate Cancer Group. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 3: extraprostatic extension, lymphovascular invasion and locally advanced disease. Mod Pathol. 2011;24(1):26-38. doi: 10.1038/ modpathol.2010.158</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; ISUP Prostate Cancer Group. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011;24(1):39-47. doi: 10.1038/modpathol.2010.160</mixed-citation><mixed-citation xml:lang="en">Berney DM, Wheeler TM, Grignon DJ, Epstein JI, Griffiths DF, Humphrey PA, van der Kwast T, Montironi R, Delahunt B, Egevad L, Srigley JR; ISUP Prostate Cancer Group. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes. Mod Pathol. 2011;24(1):39-47. doi: 10.1038/modpathol.2010.160</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI; ISUP Prostate Cancer Group. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011;24(1):48-57. doi: 10.1038/modpathol.2010.155</mixed-citation><mixed-citation xml:lang="en">Tan PH, Cheng L, Srigley JR, Griffiths D, Humphrey PA, van der Kwast TH, Montironi R, Wheeler TM, Delahunt B, Egevad L, Epstein JI; ISUP Prostate Cancer Group. ISUP Prostate Cancer Group. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 5: surgical margins. Mod Pathol. 2011;24(1):48-57. doi: 10.1038/modpathol.2010.155</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Bullock M., Srigley JR., Klotz L., Goldenberg L. Pathologic Effects of Neoadjuvant Cyproterone Acetate on Nonneoplastic Prostate, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma. Am J Surg Pathol. 2002;26(11):1400-13.</mixed-citation><mixed-citation xml:lang="en">Bullock M., Srigley JR., Klotz L., Goldenberg L. Pathologic Effects of Neoadjuvant Cyproterone Acetate on Nonneoplastic Prostate, Prostatic Intraepithelial Neoplasia, and Adenocarcinoma. Am J Surg Pathol. 2002;26(11):1400-13.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Magi-Galluzzi C., Sanderson H., Epstein JI. Atypia in Nonneoplastic Prostate Glands After Radiotherapy for Prostate Cancer: Duration of Atypia and Relation to Type of Radiotherapy. Am J Surg Pathol. 2003;27(2):206-12. 40. Hopkins Medicine. Available at: http://www. hopkinsmedicine.org/hmn/F02/feature2.html Accessed 4 Feb, 2018</mixed-citation><mixed-citation xml:lang="en">Magi-Galluzzi C., Sanderson H., Epstein JI. Atypia in Nonneoplastic Prostate Glands After Radiotherapy for Prostate Cancer: Duration of Atypia and Relation to Type of Radiotherapy. Am J Surg Pathol. 2003;27(2):206-12. 40. Hopkins Medicine. Available at: http://www. hopkinsmedicine.org/hmn/F02/feature2.html Accessed 4 Feb, 2018</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
